**The roles of a psychiatrist in the COVID-19 pandemic**

David S. Baldwin a, b, Robert Gordon b, Karl Marlowe b

1. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom
2. Southern Health Foundation Trust, Tatchbury Mount, Southampton, United Kingdom

To be submitted to *Clinics in Integrated Care*, December 2020

**Abstract**. The COVID-19 pandemic and its restrictions have strained personal psychological resilience, tested family relationships, fragmented local communities, disrupted schools and other educational institutions, exhausted health and social services, and drained national economies. Initial concerns necessarily focused on the ability of primary care services and general hospitals to cope with a potentially overwhelming wave of physically unwell patients. Attention is now being drawn to adverse effects of the pandemic on individual and societal mental health. Mental health services have important roles in mitigating adverse effects of the pandemic and measures such as enforced isolation and regional lockdown on individual mental health, in supporting the recovery of psychologically affected individuals and an exhausted health workforce, and in fostering community resilience and cohesiveness.

*(120 words)*

**Key words**: COVID-19, mental health services, neuropsychiatry, pandemic, psychiatrist

**Key points**:

* The COVID-19 pandemic and the associated restrictions together have adverse effects on mental health
* SARS-CoV-2 infection can lead to broad range of neurological and psychiatric conditions
* Patients with psychiatric conditions may be a greater risk of infection and more severe illness
* Medicines used to counter the features of COVID-19 infection may interact with psychotropic drugs
* Mental health professionals can support distressed colleagues working in the general hospital

**Background**. Prior to the COVID-19 pandemic, previous coronavirus epidemics had been associated with high rates of psychiatric morbidity1. There is accumulating evidence of higher rates of symptoms of common mental health problems such as anxiety and insomnia2, 3, 4 associated with the current viral (SARS-CoV-2) pandemic, with some reports of more severe psychiatric disorders including mania and psychosis5, 6, 7. These may arise directly from the effects of infection with enforced isolation and quarantine after viral exposure, or indirectly from additional stressors such as complicated bereavement, job losses, intra-familial tension and sudden impoverishment. So how may a psychiatrist make a useful contribution, both in the midst and aftermath of a viral pandemic?

**Neuropsychiatric disorders associated with SARS-CoV2 infection**. Central effects of viral infection and of its complications and treatments include the development of a range of neurological and psychiatric conditions, including anxiety disorders, delirium (which is probably the most commonly associated neuropsychiatric syndrome), demyelination, depressive disorders, encephalopathies, seizures and stroke1, 8, 9, 10. The psychiatrist therefore has a role in assisting neurologists to determine whether incidental mental state presentations within the context of established Covid-19 infection are best understood as either neurological or psychiatric in origin. They are also able to advise on the optimal management of patients experiencing acute confusional states which may be accompanied by marked agitation and psychotic symptoms such as troubling persecutory delusions and distressing visual hallucinations. High rates of anxiety, depressive and post-traumatic symptoms11, cognitive difficulties12, and marked fatigue13 are all reported in people who recover after hospital admission for COVID-19: although the course of these features is not yet fully established, it is probable that mental health professionals will make important contributions to supporting the community rehabilitation of discharged inpatients.

**Psychological consequences of quarantine, isolation and ‘lockdown’**. Prolonged enforced isolation and quarantine have a range of untoward effects on psychological wellbeing: anxiety, irritability, poor concentration, fatigue and lowered mood are all common14, 15. Population-based data accrued during the first month (straddling March-April 2020) of the UK-wide lockdown found that certain groups were more likely to report suicidal thoughts and self-harm: including Black, Asian and minority ethnic (BAME) groups, and people experiencing socioeconomic disadvantage, disability, physical illness, mental disorders and a COVID-19 diagnosis16. The untoward effects of isolation can be minimised by keeping its duration as short as possible, by ensuring individuals understand fully where quarantine is essential, by ensuring adequate supplies of basic needs, and by reducing boredom and improving communication. The psychiatrist should work with other mental health professionals in helping populations understand that many of the experiences are shared by others and are likely to resolve as entry back into wider society becomes possible. Simple advice on how to cope with social distancing requirements and to maintain or enhance mental well-being may help mitigate some of the adverse consequences of isolation (Table 1)17, 18.

**Patients with mental health problems before the pandemic**. The potential adverse psychological impact of viral infection in patients with established psychiatric illnesses is uncertain: individuals with known mental health problems may be particularly vulnerable to infection3, 19, this increased risk being independent of known physical health factors for COVID-193. Patients with existing mental health problems are probably more likely to be affected adversely by ‘social distancing’ and to suffer from the economic constraints resulting from the pandemic20. Individuals from BAME backgrounds are at greater risk of the more severe consequences of COVID-19 infection, and patients with mental health problems from these communities may be at even greater risk when compared with other ethnic groups21.

**Effects on mental health services**. The effects of the pandemic on the risks of relapse or recurrence of illness, or the need for increased use of services in patients with known mental health problems are not fully established22, 23. However, reports from mental health services in the United Kingdom have indicated initial falls in activity following the first national lockdown, but a subsequent increased demand for some services: with shifts from face-to-face appointments to on-line consultations, and a possible rise in mortality24-27. Psychiatrists therefore need to be vigilant in their concerted monitoring of known patients, and able to work flexibly using novel approaches to meet potentially increased demands on mental health services. They should strive to minimise relapse and so prevent avoidable admissions to potentially hazardous hospital environments where physical distancing may be hard. They also need to be assertive when protecting staff and environmental resources, during a period when these might be vulnerable to diversion to more obviously ‘frontline’ physical health services.

**Psychotropic drug prescribing during the pandemic**. Safe and effective treatment of patients with psychotropic medication may sometimes be jeopardised because of the pandemic28. Prescriptions of certain psychotropic drugs – including lithium and clozapine – need to be accompanied by regular blood testing to monitor levels and optimise tolerability and safety, and adequate provisions must be made for continued venesection using ‘Covid-secure’ means with personal protective equipment (PPE). Prescription of long-acting injectable and depot intramuscular preparations of antipsychotic medicines involves regular physical contact between patients and administering staff, so will also be reliant on use of PPE in Covid-secure environments. Guidance (some of which is summarised in Table 2) on the use of commonly prescribed psychotropic drugs (including antidepressants, antipsychotics, anxiolytics, lithium and psychostimulants) during the pandemic is available through the Royal College of Psychiatrists29.

**Interactions with medicines used to treat COVID-19 infection**. A psychiatrist should be aware of potential interactions with psychotropic medications, should a patient become infected. Many of the experimental approaches to treating Covid-19 infection – including use of azithromycin, hydroxychloroquine and remdesivir - are associated with risk of untoward interactions with concomitantly prescribed psychotropic medication. As examples, azithromycin is associated with QTc prolongation on the ECG, a phenomenon seen with a number of antipsychotic and antidepressant drugs, and its combination with these medicines may further increase the of cardiac problems; the antidepressants amitriptyline, bupropion, duloxetine, fluoxetine and paroxetine can inhibit the metabolism of hydroxychloroquine so raising its levels and increasing its risk of QTc prolongation; and remdesivir may enhance the metabolism of the antipsychotic drug clozapine, thereby potentially reducing its efficacy30.

**Supporting distressed health professionals**. During peaks of the pandemic, health professionals can find themselves working at pace outside their primary training and expertise, with rapidly changing guidance and limited equipment and other resources: troubled by doubt, uncertainty and disquiet. Health care workers may also be particularly affected by requirements for isolation and quarantine, perhaps because of concerns about being away from the workplace at a time of heightened demand15.The pandemic places many healthcare professionals in previously unanticipated situations, needing to make swift difficult decisions on rather limited evidence under duress, sometimes having to choose between similarly affected patients when allocating limited resources, whilst trying to balance their commitment to providing clinical care with their own physical and mental needs, and those of family members. These pressing challenges may cause some to experience ‘moral injury’ (psychological distress resulting from actions which violate individual moral or ethical code) and may contribute to subsequent mental health problems31. Consultation-liaison psychiatric services and occupational mental health services may therefore be important in attending to distressed colleagues, and in supporting managerial systems (from induction processes to ‘post-vention’ support of distressed staff) designed to support a psychologically robust workforce32.

**Fostering community resilience and cohesiveness**. The COVID-19 pandemic arose during ‘an age of anxiety’, with pressing global concerns relating to widening inequality, environmental degradation, terrorism, racism, xenophobia and societal polarisation: it is probable that adverse consequences of the pandemic on individual mental health will combine synergistically with these factors to engender a pervasive societal sense of unease33. Psychiatrists and other mental health professionals should therefore contribute to efforts to recognise that individual distressed mental states must be placed in a wider social context, and to foster understanding of how the individual and the collective are mutually dependent.

**Conclusion**. Few would have anticipated that a simple virus could wreak such world-wide damage. The global transmission of SARS-CoV-2 has transformed societies and imposed major challenges to health services. The adverse consequences of the pandemic, with its necessary accompanying restrictions, on individual psychological well-being are becoming more apparent. Psychiatrists and other mental health professionals have a key role in providing advice on the management of patients with emergent neuropsychiatric syndromes associated with viral infection, in caring for patients with mental health problems who are at increased risk of infection and of the deleterious consequences of isolation and lockdowns, in supporting other health professionals who may be distressed and exhausted by the nature and volume of their work, and in helping battered communities to recover from this unexpected onslaught.

*(1428 words excluding abstract, key words, key points, references and tables)*

**Table 1. Simple steps to maintain well-being whilst ‘social distancing’**

1. Establish a regular daily routine to provide structure and purpose
2. Balance commitments over a week to ensure a good mix of work, rest and leisure
3. Continue important regular activities, adapting them to be carried out at home
4. Set daily goals to provide a sense of progress and achievement
5. Acquire new knowledge to give a sense of growth
6. Keep in touch with family and friends and talk about feelings and concerns
7. Volunteer time and skills to support others
8. Look after physical health through having a healthy diet and taking regular exercise
9. Identify potential triggers of low mood and take steps to reduce them
10. Avoid excessive consumption of alcohol-containing drinks

**Table 2. Summarised guidance on psychotropic drug prescribing to adults during the pandemic era**

For a full account, visit <https://www.rcpsych.ac.uk/about-us/responding-to-covid-19/responding-to-covid-19-guidance-for-clinicians/community-and-inpatient-services/providing-medication>

*Antidepressant, anxiolytic or antipsychotic medication*. Careful consideration should be given to whether now is the best the time to withdraw or change medication. For many patients it is likely that advice will be given to continue on regular medication until this can be reviewed in a face-to-face setting and the patient can be involved in shared decision making with their usual doctor or healthcare provider.

*Benzodiazepines and/or rapid tranquilisation*. Patients should have increased physical health monitoring and this should be reflected in the patient’s individualised care plan.

*Lithium*. Febrile patients may become dehydrated and lithium levels may rise, putting patients at greater risk of toxicity. Look for signs of potential toxicity such as coarse tremor. If these are present obtain an urgent lithium level.

*Clozapine*. It is highly unlikely that during this period it will be possible to start patients on clozapine treatment safely unless normal haematological monitoring can be assured.

*Patients with cognitive impairment*. It is likely that people with underlying cognitive impairment will be at increased risk of delirium if suffering from COVID-19 related illness. It will be important when deciding on the best management plan (both non pharmacological and pharmacological) to consider all the relevant factors including risk to self and to others.

*Injectable treatments*. If the patient describes COVID-19 symptoms, and is due to have their depot/long-acting injectable (LAI) administered, consult the prescriber and consider an alternative short term treatment plan, such as deferring treatment for 2 weeks (if currently psychologically well and risk of rapid relapse is considered low) or switching to oral formulations (refer to guidance about dosage equivalence). If the decision is made to defer depot/LAI, ensure a clear plan/risk assessment is agreed and documented regards follow up with continued monitoring of mental and physical health, with the agreed date of when to review and next administer depot/LAI.

**References**

1. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020; **7**: 611-27.
2. Wang C, Pan R, Wan X et al. Immediate psychological responses an associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. *Int J Environ Res Public Health* 2020; **17**: 1729.
3. Taquet M, Luciano S, Geddes JP, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. *Lancet Psychiatry*. Nov 9, 2020: [https://doi.org/10.1016/S2215-0366(20)30462-4](https://doi.org/10.1016/S2215-0366%2820%2930462-4).
4. Lin L-Y, Wang J, Ou-Yang X-Y, et al. The immediate impact of the 2019 novel coronavirus (COVI-19) outbreak on subjective sleep status. *Sleep Med* 2020; <https://doi.org/10.1016/j.sleep.2020.05.018>.
5. Iqbal Y, Al Adbulla MA, Abrahim A, et al. Psychiatric presentation of patients with SARS-CoV-2 infection: a retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team. *BJPsych Open* 2020; 6 (5). E109.
6. Smith CM, Komisar JR, Mourad A, Kincaid BR. COVID-19-associated brief psychotic disorder. *BMJ Case Rep* 2020; 13:e236940.doi:10.1136/bcr-2020-236940.
7. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by the novel coronavirus infection and the inflammatory response? *Psychosomatics* 2020; **61**: 551-5.
8. Varatharaj A, Thomas N, Ellul MA, Davies NSW, Pollak TA et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry* 2020; **7**: 875-82.
9. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. *J Neurol Sci* 2020; **413**: 116832.
10. Nalleballe K, Onteddu SJ, Sharma S et al. Spectrum of neuropsychiatric manifestations in COVID-19. *Brain Behav Immun* 2020; **88**: 71-4.
11. Mazza MG, De Lorenzo R, Conte C et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. *Brain Behav Immun* 2020; SO889-1591(20)31606-8.doi: 10.1016/j.bbi.2020.07.037 pmid: 32738287.
12. Halpin SJ, McIvor C, Whyatt G et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. *J Med Virol* 2020. Doi: 10.1002/jmv.26368 pmid: 32729939.
13. Zhou H, Lu S, Chen J et al. The landscape of cognitive function in recovered COVID-19 patients. *J Psychiatr Res* 2020; **129**: 98-102.
14. Leigh-Hunt N, Bagguley D, Bash K, et al. An overview of systematic reviews on the public health consequences of social isolation and loneliness. *Public Health* 2017; **152**: 157-71.
15. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet* 2020; **395**: 912–20.
16. Iob E, Steptoe A, Fancourt D. Abuse, self-harm and suicidal ideation in the UK during the COVID-19 pandemic. *Br J Psychiatry* 2020; **217**: 543-6.
17. Tappenden I, Tomar R. Mental health impacts of social isolation in older people during COVID pandemic. *Prog Neurol Psychiatr* 2020; **24**: 25-9.
18. Diamond R, Willan J. Coronavirus disease 19: achieving good mental health during social isolation. *Br J Psychiatry* 2020; **217**: 408-9.
19. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. *World Psychiatry* 2020; published online Oct 7.https://doi.org/10.1002.wps.20806.
20. Gayer-Anderson C, Latham R, El Zerbi C, et al. Impacts of social isolation among disadvantaged and vulnerable groups during public health crises. ESRC 2020; <https://esrc.ukri.org/files/news-events-and-publications/evidence-briefings/impacts-of-social-isolation-among-disadvantaged-and-vulnerable-groups-during-public-health-crises/>
21. Kapilashrami A, Bhui K. Mental health and COVID-19: is the virus racist? *Br J Psychiatry* 2020; **217**: 405-7.
22. Kaufman KR, Petkova E, Bhui KS, Schulze TG. A global needs assessment in times of a global crisis: world psychiatry response to the COVID-19 pandemic. *BJPsych Open* (2020) 6, e48, 1–3. doi:10.1192/bjo.2020.25.
23. Holmes EA, O'Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry* 2020; **7**: 547-60.
24. Chen S, Jones PB, Underwood BR, et al. The early impact of COVID-19 on mental health and community physical health services and their patients’ mortality in Cambridgeshire and Peterborough, UK. *J Psychiatr Res* 2020; 22 Sep 2020: https://doi.org/10.1016/j.jpsychires.2020.09.020.
25. Stewart R, Martin E, Bakolis I, Broadbent M, Byrne N, Landau S. Comparison of mental health service activity before and shortly after UK social distancing responses to the COVID-19 pandemic: February-March 2020. medRxiv 2020; 28 Sep 2020: https://www.medrxiv.org/content/10.1101/2020.09.26.20202150v1.
26. Stewart R, Broadbent M, Das-Munshi J. Excess mortality in mental health service users during the COVID-19 pandemic described by ethnic group: South London and Maudsley data. medRxiv 2020; 14 Jul 2020: https://medrxiv.org/cgi/content/short/2020.07.13.20152710v1.
27. Stewart R, Martin E, Broadbent M. Mental health service activity during COVID-19 lockdown: South London and Maudsley data on working age community and home treatment team services and mortality from February to mid-May 2020. medRxiv 2020; 16 Jun 2020: <https://www.medrxiv.org/content/10.1101/2020.06.13.20130419v1>.
28. Luykz JJ, van Veen SMP, Risselada A et al. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. *Br J Psychiatry* 2020; **217**: 471-4.
29. Royal College of Psychiatrists. COVID-19: providing medication. <https://www.rcpsych.ac.uk/about-us/responding-to-covid-19/responding-to-covid-19-guidance-for-clinicians/community-and-inpatient-services/providing-medication> (accessed 24/11/20).
30. Bishara D, Kalafatis C, Taylor D. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. *Ther Adv Psychopharmacol* 2020; **10**: 1–15. DOI: 10.1177/2045125320935306.
31. Greenberg N, Docherty M, Gnanapragasam S, Wessely S. Managing mental health challenges faced by healthcare workers during covid-19 pandemic. *BMJ* 2020;368:m1211.
32. Tracy DK, Tarn M, Eldridge R et al. What should be done to support the mental health of health-care staff treating COVID-19 patients? *Br J Psychiatry* 2020; **217**: 537-9.
33. Kesner L, Horacek J. Three challenges that the COVID-19 pandemic represents for psychiatry. *Br J Psychiatry* 2020; **217**: 475-6.